All Stories

  1. Toward a cure for diabetes: iPSC and ESC‐derived islet cell transplantation trials
  2. The Ulaanbaatar agreement: Revising diabetes terminology in Asia to combat stigma
  3. Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan
  4. PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice
  5. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice
  6. Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic MEN1 Mutation
  7. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)
  8. A Study on the Compatibility of a Food-Recording Application with Questionnaire-Based Methods in Healthy Japanese Individuals
  9. Obsessive‐compulsive disorder as an initial manifestation of anti‐glutamic acid decarboxylase antibody‐associated encephalitis
  10. PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
  11. Japanese 17q12 Deletion Syndrome with Complex Clinical Manifestations
  12. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
  13. Visceral Adipose Tissue Quality and its Impact on Metabolic Health
  14. Primary aldosteronism patients with previous cardiovascular and cerebrovascular events have high aldosterone responsiveness to ACTH stimulation
  15. [<sup>18</sup>F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature
  16. Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes–Evidence from a large national database in Japan
  17. Glucokinase Variant Proteins Are Resistant to Fasting-Induced Uridine Diphosphate Glucose-Dependent Degradation in Maturity-Onset Diabetes of the Young Type 2 Patients
  18. Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes
  19. Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice
  20. Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
  21. Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
  22. Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus
  23. Efficacy and Safety of 6-Month High Dietary Protein Intake in Hospitalized Adults Aged 75 or Older at Nutritional Risk: An Exploratory, Randomized, Controlled Study
  24. Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan
  25. Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
  26. Two cases of systemic lupus erythematosus after administration of severe acute respiratory syndrome coronavirus 2 vaccine
  27. Editorial: Advances in the research of diabetic nephropathy, volume II
  28. Editorial: Advances in the research of diabetic nephropathy
  29. Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
  30. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study
  31. Cover Image, Volume 24, Issue 12
  32. An analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging
  33. Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment
  34. Advances in insulin therapy from discovery to β‐cell replacement
  35. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan
  36. d-Allulose Inhibits Ghrelin-Responsive, Glucose-Sensitive and Neuropeptide Y Neurons in the Arcuate Nucleus and Central Injection Suppresses Appetite-Associated Food Intake in Mice
  37. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
  38. Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan
  39. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials
  40. Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
  41. Effects of physician’s diabetes self‐management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self‐monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exp...
  42. Voxel‐based specific regional analysis system for Alzheimer’s disease utility as a screening tool for unrecognized cognitive dysfunction of elderly patients in diabetes outpatient clinics: Multicenter retrospective exploratory study
  43. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?
  44. Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids
  45. Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
  46. The Role of Metagenomics in Precision Nutrition
  47. Tumor‐like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin‐induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat
  48. Alcohol‐induced impaired insulin secretion in a Japanese population: 5‐year follow up in the Gifu Diabetes Study
  49. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
  50. Utility of microcatheter in adrenal venous sampling for primary aldosteronism
  51. Factory-calibrated continuous glucose monitoring and capillary blood glucose monitoring in a case with insulinoma: usefulness and possible pitfall under chronic hyperinsulinemic hypoglycemia
  52. Low-carbohydrate diet by staple change attenuates postprandial GIP and CPR levels in type 2 diabetes patients
  53. GPR40 activation initiates store-operated Ca2+ entry and potentiates insulin secretion via the IP3R1/STIM1/Orai1 pathway in pancreatic β-cells
  54. Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
  55. The journey to understanding incretin systems: Theory, practice and more theory
  56. Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
  57. A rare case of autoimmune polyglandular syndrome with Sjögren’s syndrome and primary hypoparathyroidism
  58. Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion
  59. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
  60. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
  61. Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init
  62. Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan
  63. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
  64. Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation
  65. Beta-cell replacement strategies for diabetes
  66. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
  67. Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?
  68. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation
  69. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl
  70. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases
  71. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial)
  72. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study
  73. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial
  74. Cardiovascular safety trials of incretin-based drugs: What do they mean?
  75. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
  76. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin
  77. Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
  78. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation
  79. Type 2 diabetes via β-cell dysfunction in east Asian people
  80. Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance
  81. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
  82. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan
  83. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation
  84. Evidence-based practice guideline for the treatment for diabetes in Japan 2013
  85. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study
  86. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
  87. β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
  88. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events
  89. A case of hypoglycemia due to illegitimate sexual enhancement medication
  90. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
  91. A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease
  92. Alogliptin for the treatment of Type 2 diabetes
  93. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of G et G oal‐ S
  94. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP ‐4 inhibitors with other oral antidiabetic drugs
  95. Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
  96. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus
  97. The role of chronobiology and circadian rhythms in type 2 diabetes mellitus: implications for management of diabetes
  98. Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
  99. Relationship and factors responsible for regulating fasting and post‐challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus
  100. Alogliptin benzoate for the treatment of type 2 diabetes
  101. Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
  102. Circulating TNF Receptor 2 is Closely Associated with the Kidney Function in Non-Diabetic Japanese Subjects
  103. Incretin actions beyond the pancreas: lessons from knockout mice
  104. Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: Implications for glucagon-like peptide-1 secretion from pancreatic α cells in vivo
  105. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function
  106. Improvement of Fasting Plasma Glucose Level After Ingesting Moderate Amount of Dietary Fiber in Japanese Men With Mild Hyperglycemia and Visceral Fat Obesity
  107. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
  108. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes
  109. Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
  110. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
  111. Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
  112. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
  113. Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese
  114. Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: Potential mechanism of resistance to weight loss among Japanese obese smokers
  115. Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation
  116. Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener
  117. Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
  118. Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
  119. Circadian rhythms and diabetes
  120. Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance
  121. GIP and GLP-1, the two incretin hormones: Similarities and differences
  122. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
  123. The Role of Family Nutritional Support in Japanese Patients with Type 2 Diabetes Mellitus
  124. Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
  125. Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase
  126. A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion
  127. Rbp-j regulates expansion of pancreatic epithelial cells and their differentiation into exocrine cells during mouse development
  128. Multiple roles of Notch signaling in cochlear development
  129. Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARP
  130. Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling
  131. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
  132. Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas
  133. Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas
  134. Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol
  135. Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis
  136. Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterols
  137. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins
  138. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER
  139. Crucial Step in Cholesterol Homeostasis
  140. Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes
  141. DANCE, a Novel Secreted RGD Protein Expressed in Developing, Atherosclerotic, and Balloon-injured Arteries
  142. Molecular Cloning, Characterization, and Chromosomal Localization of FKBP23, a Novel FK506-Binding Protein with Ca2+-Binding Ability
  143. Human Calumenin Gene (CALU): cDNA Isolation and Chromosomal Mapping to 7q32
  144. Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant
  145. Calumenin, a Ca2+-binding Protein Retained in the Endoplasmic Reticulum with a Novel Carboxyl-terminal Sequence, HDEF